Last updated: April 22, 2026
Nilotinib D-tartrate is supplied through three tiers: API (nilotinib free base or API salt), salt conversion (to D-tartrate), and finished dosage manufacturing (for tablets/capsules where applicable). Publicly available supplier attribution is uneven: many vendors sell nilotinib API without prominently listing the D-tartrate salt form, while others market finished product. Under a strict patent-analysis lens, the actionable approach is to map (1) API suppliers that can supply nilotinib (free base) at commercial scale and (2) salt/conversion vendors that can produce nilotinib D-tartrate under cGMP, then (3) finished-dose contract manufacturers for the specific tablet strength and dosage form.
Which companies supply nilotinib API at commercial scale?
The most robust public signal comes from API manufacturers and large chemical suppliers that list nilotinib as an available API product (typically as nilotinib free base). These suppliers are the primary candidates for producing or enabling nilotinib D-tartrate via salt formation, because D-tartrate conversion is generally a downstream salt process rather than a distinct molecule from a supply-chain perspective.
API supply candidates commonly used in industry due diligence
- Siegfried (API and intermediates; European footprint)
- Dr. Reddy’s Laboratories (global generics and API manufacturing; also active in salt/process capabilities across programs)
- Boehringer Ingelheim supply chain partners (for product-level continuity in branded workflows, where applicable)
- Generic API vendors that list nilotinib as purchasable API (typically sell nilotinib free base; salt form produced by the purchaser or downstream partner)
Key constraint for D-tartrate specificity
Many supplier catalog pages list nilotinib (free base) without specifying the salt. A buyer that needs nilotinib D-tartrate should treat “nilotinib API” listings as a starting point and then validate:
- salt form identity (DSC, XRPD, Raman/IR, NMR confirmation)
- polymorph/hydrate state (XRPD patterns and stress-test results)
- particle size and tabletability specs
- residual solvents and elemental impurities aligned with ICH Q3D
- lead time and supply continuity for the exact salt
Do finished-dose suppliers specifically provide nilotinib D-tartrate?
Finished product supply is more publicly traceable because branded products use fixed salt forms. For nilotinib-based therapies, branded labeling historically uses nilotinib hydrochloride; D-tartrate is used in some regional registrations and supplier offerings. As a result, finished-dose suppliers may or may not sell “nilotinib D-tartrate” as the marketed salt. The practical buyer path is to:
1) identify the regional market authorization(s) that explicitly list D-tartrate, then
2) trace the manufacturer of the finished dosage unit via local regulatory filings and product labels, then
3) map whether the manufacturer sources API under a contract supply agreement or makes in-house.
Public regulatory traceability is the decisive method when salt form is contract-critical, because catalog listings alone are insufficient to prove D-tartrate identity at batch level.
Which intermediates or process inputs drive the nilotinib salt conversion supply?
Salt formation and stabilization for nilotinib D-tartrate require control of:
- tartrate source quality (D-tartaric acid; optical purity)
- solvent selection for salt crystallization
- filtration and drying parameters to hit a repeatable XRPD fingerprint
- impurity profile management during crystallization
Because the conversion step is sensitive, companies that offer “salt screening and scale-up” for APIs are often the practical bottleneck, even when nilotinib free base is readily available.
Salt-conversion capability checks
- cGMP salt formation and crystallization
- chiral control for D-tartaric acid
- validated analytical package:
- XRPD (polymorph and crystallinity)
- DSC/DTG
- HPLC for nilotinib assay and related impurities
- residual solvents (GC per ICH Q3C)
- water activity or KF moisture for drying verification
What due-diligence requirements determine whether a vendor can supply nilotinib D-tartrate (not just nilotinib)?
A procurement-grade verification package typically includes:
Documents to require before commercial commitment
- Certificate of Analysis (CoA) for at least 3 consecutive batches
- manufacturing site GMP compliance (GMP certificate and inspection history)
- salt identity confirmation report:
- XRPD and reference standard traceability
- DSC thermogram comparison to qualified reference material
- impurity profile including:
- specified related impurities
- control strategy for degradation products
- stability program summaries for:
- 25°C/60% RH and 30°C/65% RH or ICH-aligned long-term/accelerated conditions
- residual solvents and elemental impurities results aligned to ICH Q3D and Q3C
How to structure a sourcing plan when D-tartrate specificity is critical
A procurement strategy that reduces execution risk is to separate roles:
Option A: API supplier + salt conversion partner
- Buy nilotinib free base API from a commercial API supplier
- Convert to nilotinib D-tartrate at a cGMP salt-forming site
- Use a third-party testing lab or internal QC for XRPD/DSC confirmation against a locked specification
Option B: Direct API-salt supply
- Source nilotinib D-tartrate API from a vendor that explicitly qualifies the salt
- Validate polymorph and hydrate state via XRPD and stability commitments
- Confirm supply continuity and change-control obligations
Option C: Finished dosage supplier
- Contract with a CDMO that manufactures the required dosage form (tablet strength, packaging) using nilotinib D-tartrate
- Confirm the API salt form in the executed batch records and CoA release tests
A practical “supplier qualification” matrix (what to test, not what to hope)
| Requirement |
Minimum proof a buyer should request |
Why it matters for D-tartrate |
| Salt identity |
XRPD and DSC matched to qualified reference |
Prevents wrong polymorph/salt form substitution |
| Chiral acid |
Certificate of analysis for D-tartaric acid input |
Optical purity can change crystallization behavior and impurities |
| Particle and flow |
PSD (laser diffraction) and bulk/tapped density |
Drives mixing, drying, and tablet uniformity |
| Impurities |
CoA impurity table per batch |
Salt formation can shift impurity profile and degradation behavior |
| Stability |
Accelerated and long-term data |
Confirms physical stability and no salt interconversion |
Supply chain risk signals to flag in vendor negotiations
- No explicit D-tartrate specification in the CoA template
- Only “nilotinib API” listed without salt-form analytical evidence
- Lack of change-control commitments for:
- crystallization solvent system
- drying conditions
- supplier of D-tartaric acid
- No XRPD reference standard or no ability to provide matched patterns
- Lead time instability without scheduled allocation or back-up manufacturing sites
Key Takeaways
- Public vendor listings for nilotinib often cover the free base; nilotinib D-tartrate supply must be proven with salt-form analytical evidence (XRPD/DSC) and batch-level CoAs.
- The most reliable execution model is “nilotinib free base API supply plus cGMP salt conversion” unless a supplier explicitly qualifies nilotinib D-tartrate API for commercial use.
- Procurement-grade qualification for D-tartrate requires validated salt identity, polymorph control, and stability data, not just a catalog claim.
FAQs
1) Can an API supplier of nilotinib free base be used to obtain nilotinib D-tartrate?
Yes, if paired with a cGMP salt-formation partner that can reliably convert and lock the D-tartrate form using validated crystallization and analytical controls.
2) What analytical methods matter most for nilotinib D-tartrate confirmation?
XRPD and DSC are the core identity checks; they should be matched to a qualified reference and shown across multiple batches. Supporting checks include impurity profiling and residual solvent testing.
3) Do suppliers that list “nilotinib API” necessarily supply the D-tartrate salt?
No. Catalog availability for nilotinib does not prove salt form. D-tartrate needs explicit confirmation in CoA and method results.
4) What is the biggest operational risk in D-tartrate sourcing?
Polymorph/hydrate drift from crystallization and drying variability, leading to nonconformance against XRPD/DSC and reduced downstream batch acceptance.
5) What should be included in a salt conversion vendor’s change-control agreement?
Crystallization and solvent system, drying parameters, D-tartaric acid source, and analytical method/acceptance criteria, plus notification and requalification triggers.
References
[1] ICH Harmonised Guideline. Q3C(R8) Impurities: Guideline for Residual Solvents. International Council for Harmonisation, 2011 (updated).
[2] ICH Harmonised Guideline. Q3D(R2) Impurities: Elemental Impurities. International Council for Harmonisation, 2022.
[3] ICH Harmonised Guideline. Q1A(R2) Stability Testing of New Drug Substances and Products. International Council for Harmonisation, 2003 (revised).
